Compare Stocks: CUE, LXEO, XFOR, and RCKT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$28.16 -2.4%	$29.32	$4.97 ▼ $45.50	$209.58M	2.47	218,341 shs	225,427 shs
LXEO Lexeo Therapeutics	$4.99 -0.4%	$4.74	$3.99 ▼ $10.99	$411.05M	1.46	907,139 shs	1.11 million shs
RCKT Rocket Pharmaceuticals	$3.62 -1.1%	$3.51	$2.53 ▼ $5.45	$401.77M	0.47	1.48 million shs	1.26 million shs
XFOR X4 Pharmaceuticals	$4.23 +1.4%	$4.09	$2.80 ▼ $4.83	$413.44M	0.37	704,799 shs	597,226 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	-2.39%	+14.43%	-6.91%	+28.58%	-96.23%
LXEO Lexeo Therapeutics	-0.40%	-1.38%	+13.67%	-2.92%	+2.89%
RCKT Rocket Pharmaceuticals	-1.09%	+4.02%	+15.29%	+17.92%	+9.04%
XFOR X4 Pharmaceuticals	+1.44%	+4.96%	+7.63%	-1.86%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$28.16 -2.4%	$29.32	$4.97 ▼ $45.50	$209.58M	2.47	218,341 shs	225,427 shs
LXEO Lexeo Therapeutics	$4.99 -0.4%	$4.74	$3.99 ▼ $10.99	$411.05M	1.46	907,139 shs	1.11 million shs
RCKT Rocket Pharmaceuticals	$3.62 -1.1%	$3.51	$2.53 ▼ $5.45	$401.77M	0.47	1.48 million shs	1.26 million shs
XFOR X4 Pharmaceuticals	$4.23 +1.4%	$4.09	$2.80 ▼ $4.83	$413.44M	0.37	704,799 shs	597,226 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	-2.39%	+14.43%	-6.91%	+28.58%	-96.23%
LXEO Lexeo Therapeutics	-0.40%	-1.38%	+13.67%	-2.92%	+2.89%
RCKT Rocket Pharmaceuticals	-1.09%	+4.02%	+15.29%	+17.92%	+9.04%
XFOR X4 Pharmaceuticals	+1.44%	+4.96%	+7.63%	-1.86%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	1.00	Sell	N/A	N/A
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	275.75% Upside
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.57	136.78% Upside
XFOR X4 Pharmaceuticals	2.50	Moderate Buy	$11.25	165.96% Upside

Current Analyst Ratings Breakdown

Latest CUE, LXEO, XFOR, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$27.47M	7.44	N/A	N/A	$0.32 per share	88.00
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$2.87 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$3.36 per share	N/A
XFOR X4 Pharmaceuticals	$35.11M	11.95	N/A	N/A	$1.57 per share	2.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$26.60M	-$27.02	N/A	N/A	N/A	-435.83%	-620.06%	-291.15%	11/12/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)
XFOR X4 Pharmaceuticals	-$79.20M	-$1.20	N/A	N/A	N/A	-568.80%	-63.05%	-36.89%	11/4/2026 (Estimated)

Latest CUE, LXEO, XFOR, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A
8/7/2026	Q2 2026	XFOR X4 Pharmaceuticals	-$0.1760	-$0.13	+$0.0460	-$0.13	$2.42 million	$8.81 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	N/A	1.25	1.25
LXEO Lexeo Therapeutics	N/A	13.89	13.89
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24
XFOR X4 Pharmaceuticals	0.49	11.30	11.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
LXEO Lexeo Therapeutics	60.67%
RCKT Rocket Pharmaceuticals	98.39%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	14.56%
LXEO Lexeo Therapeutics	2.00%
RCKT Rocket Pharmaceuticals	21.30%
XFOR X4 Pharmaceuticals	1.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	7.26 million	6.21 million	Optionable
LXEO Lexeo Therapeutics	58	82.05 million	80.41 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	109.78 million	86.39 million	Optionable
XFOR X4 Pharmaceuticals	80	99.15 million	98.03 million	No Data

CUE, LXEO, XFOR, and RCKT Headlines

Recent News About These Companies

Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Target Price at $11.25

August 24, 2026 | americanbankingnews.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts

August 19, 2026 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) President Sells $109,117.44 in Stock

August 14, 2026 | insidertrades.com

John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

August 13, 2026 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock

August 13, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

August 11, 2026 | zacks.com

XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets

August 11, 2026 | marketbeat.com

Equities Analysts Issue Forecasts for XFOR FY2029 Earnings

August 10, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Receives a Buy from Stifel Nicolaus

August 9, 2026 | theglobeandmail.com

X4 Pharmaceuticals: Q2 Earnings Snapshot

August 6, 2026 | chron.com

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026 | markets.businessinsider.com

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

X4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Beats Expectations By $0.05 EPS

August 6, 2026 | marketbeat.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Perceptive Advisors LLC Increases Stake in X4 Pharmaceuticals, Inc. $XFOR

August 2, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

X4 Pharmaceuticals, Inc. Common Stock (XFOR) After Hours Quote

July 13, 2026 | nasdaq.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 7, 2026 | globenewswire.com

X4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 Shares

July 2, 2026 | insidertrades.com

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

July 1, 2026 | globenewswire.com

Why X4 Pharmaceuticals, Inc.’s (XFOR) Stock Is Up 5.01%

June 26, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, LXEO, XFOR, and RCKT Company Descriptions

Cue Biopharma NASDAQ:CUE

$28.16 -0.69 (-2.39%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$28.14 -0.02 (-0.07%)

As of 07:17 AM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$4.99 -0.02 (-0.40%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$4.93 -0.06 (-1.28%)

As of 07:37 AM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.62 -0.04 (-1.09%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$3.62 +0.00 (+0.14%)

As of 07:23 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

X4 Pharmaceuticals NASDAQ:XFOR

$4.23 +0.06 (+1.44%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$4.22 -0.01 (-0.12%)

As of 07:00 AM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUE, LXEO, XFOR, and RCKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUE, LXEO, XFOR, and RCKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUE, LXEO, XFOR, and RCKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, LXEO, XFOR, and RCKT Company Descriptions

Cue Biopharma NASDAQ:CUE

Lexeo Therapeutics NASDAQ:LXEO

Rocket Pharmaceuticals NASDAQ:RCKT

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUE, LXEO, XFOR, and RCKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUE, LXEO, XFOR, and RCKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUE, LXEO, XFOR, and RCKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, LXEO, XFOR, and RCKT Company Descriptions

Cue Biopharma NASDAQ:CUE

Lexeo Therapeutics NASDAQ:LXEO

Rocket Pharmaceuticals NASDAQ:RCKT

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools